The PTC platform comprises four products, the Capstone PTC Spinal System, Clydesdale PTC Spinal System, Anatomic Peek PTC Cervical Fusion System and Cornerstone-SR Ti- Coated Anatomical Cervical Cage.

The devices have been developed to treat patients experiencing pain caused by compression of the spinal cord or nerve roots, and helps to restore normal disc height.

Medtronic spine business president and senior vice-president Doug King said: "Our PTC platform of interbody spacers is the result of our relentless effort to add value to our products and respond to surgeon needs by offering the advantages of combined materials in a single implant.

"We will continue to leverage our innovation to produce more advanced and differentiated products for surgeons to use to treat their patients."

The Capstone PTC Spinal System and Clydesdale PTC Spinal System have secured US Food and Drug Administration (FDA) 510(k) approval in March, and introduced in the US in August. Both the devices received CE mark approval in July.

These devices are developed for interbody fusion with autogenous bone graft in patients with Degenerative Disc Disease (DDD) at one or two levels from L2 to S1, and for interbody fusions in the lower back or lumbar spine.

The company plans to launch the Capstone PTC Spinal System in Japan in November, while the Clydesdale PTC Spinal System in January 2016.

The Anatomic Peek PTC Cervical Fusion System has obtained FDA 510(k), and introduced in the US in September. It is indicated for degenerative discopathy and instability, as well as pseudarthrosis or failed arthrodesis.

The Cornerstone-SR Ti- Coated Anatomical Cervical Cage received CE mark approval, and is available in Western Europe. It is indicated for cervical interbody fusion procedures in skeletally mature patients with cervical disc disease at one level from the C2-C3 disc to the C7-T1 disc.

Image: The world headquarters of Medtronic, Fridley, Minnesota, USA. Photo: courtesy of Bobak Ha’Eri.